Relapsing Remitting Multiple Sclerosis News and Research

RSS
ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Adeona third quarter total net revenues increase to $289,898

Adeona third quarter total net revenues increase to $289,898

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

GfK HealthCare: RRMS patients anticipate availability of new oral therapies

GfK HealthCare: RRMS patients anticipate availability of new oral therapies

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Genmab announces Phase II ofatumumab study results in RRMS patients

Genmab announces Phase II ofatumumab study results in RRMS patients

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Initial Phase II study results of ofatumumab in patients with RRMS announced

Initial Phase II study results of ofatumumab in patients with RRMS announced

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen, Elan launch My MS Health, a web-based PRO research program